Clinical Edge Journal Scan

Rise in incidences of RA among patients who developed COVID-19


 

Key clinical point: The incidence of rheumatoid arthritis (RA) during the pandemic period was significantly higher in individuals who did vs did not develop COVID-19, with patients age 51-60 years having the seemingly highest risk.

Major finding: The incidence rates of developing seropositive RA (incidence rate ratio [IRR] 1.60; 95% CI 1.16-2.22) and unspecified RA (IRR 2.93; 95% CI 2.04-4.19) during the pandemic period (2020-2022) were significantly higher in patients with vs without previous COVID-19, with the incidence rates being the highest in the age group of 51-60 years vs the age group of 18-30 years (hazard ratio 9.16; 95% CI 7.24-11.59).

Study details: This retrospective, population-based cohort study analyzed the data of 3,335,084 individuals from the COOSALUD EPS registry (Columbia).

Disclosures: This study was supported by funds from COOSALUD EPS, Columbia. JS Marín and J-M Anaya declared employment with and receiving financial support from COOSALUD EPS, respectively.

Source: Marín JS et al. Increased incidence of rheumatoid arthritis after COVID-19. Autoimmun Rev. 2023;22(10):103409 (Aug 18). doi: 10.1016/j.autrev.2023.103409

Recommended Reading

Weight gain and increased BP concerns should not deter low-dose glucocorticoid use in RA
MDedge Rheumatology
Tapering TNFi raises disease flare likelihood in patients with RA even in those in remission
MDedge Rheumatology
No effect of initial glucocorticoid bridging on glucocorticoid use over time in RA
MDedge Rheumatology
No effect of initial glucocorticoid bridging on glucocorticoid use over time in RA
MDedge Rheumatology
Factors associated with persistent fatigue in early RA
MDedge Rheumatology
Real-world study supports tocilizumab as first-line biologic in DMARD-IR patients with RA
MDedge Rheumatology
Tofacitinib + iguratimod offers choice for dual treat-to-target in RA with usual interstitial pneumonia
MDedge Rheumatology
Circulating semaphorin 4A shows potential for predicting treatment failure in RA
MDedge Rheumatology
JAKi offer a potential therapeutic option for mitigating bone loss in RA
MDedge Rheumatology
Multimorbidity disproportionately impacts women with RA
MDedge Rheumatology